Pharmachem Technologies has started expanding its API facility in Grand Bahama just days after its main customer Gilead Sciences won US FDA approval for a new HIV drug.
Closure of its Benicar intermediates plant was prompted by impending US patent loss and a decision to focus on large molecule drugs says Daiichi Sankyo.
Aesica has doubled early formulation development capacity and added controlled drug handling capabilities at its manufacturing facility in Queenborough, UK.
Dipexium Pharmaceuticals has successfully scaled-up API for its antimicrobial peptide phase III candidate Locilex, made from the skin of the African Clawed Frog.
Drug companies were a more important source of revenue for Lonza in 2015 than in previous years with four of its five biggest spending customers coming from the pharmaceutical sector.
Compounds that leave pathogenic bacteria alive but harmless could yield antibiotics that are less likely to induce resistance development say the authors of a new study.
Pfizer has said it will invest $21m to expand a plant in Adelaide, Australia which will manufacture a candidate biosimilar version of Amgen’s white blood cell booster, Neulasta.
Pollution from antibiotic plants a hot topic at DCAT week
API makers that don’t treat wastewater to cut costs and keep prices low are spreading antibiotic resistance says DSM-Sinochem, which wants drug companies to stop buying from firms that “distort” the market.
The process of sorting out problems with the US FDA's controversial Inactive Ingredients Database (IID) is shaping up to be a huge task, particularly as the agency is working through a backlog of missing updates extending back several years.
Selling most of its API business had only a limited impact on revenues in 2015 according to BASF, which has reiterated its plan to retain its ibuprofen, PEG and omega-3 operations.
French regulators have raised concerns about heparin made by Chinese supplier Dongying Tiandong Pharmaceutical and called on the EMA to revoke its GMP certificate.
A tarantula venom toxin that inhibits a novel pain receptor will guide development of more effective non-opioid painkillers say researchers in Australia.
International Chemical Investors Group (ICIG) and Novartis Group have entered into an agreement in which ICIG will acquire all shares in Sandoz Industrial Products GmbH.
Research examining how API particle characteristics impact drug stability will help safeguard Denmark’s $12bn (DKK80bn) a year drug manufacturing industry say scientists.
ScinoPharm Taiwan announced its unaudited financial results for fiscal year 2015, and with it, plans to expand its contract businesses through strategic acquisitions.
There are concerns that pharma companies are not fully prepared to meet the new requirements on risk-assessment for excipients, even though the deadline is just a few weeks away.
Controlled substances and peptides are on AMRI’s wish list as it profits from a growth strategy which has seen six acquisitions over the past two years.
Moving its clinical manufacturing operations to its API and drug site in Queenborough has reduced the risk of problems during tech transfer and cut cycle times according to UK CMO Aesica.
Biocon, an Indian biopharmaceuticals company, has received European approvals for its Rosuvastatin Calcium, a generic equivalent of AstraZeneca’s Crestor tablets.
The global active pharmaceuticals ingredients (APIs) market was $119.7 bn in 2014 and is predicted to reach $185.9 bn by 2020, according to a new report.
Researchers have created the first robotically driven experimentation system which reduces the number of necessary experiments throughout drug discovery by 70%.
Most buildings in Taiwan are designed to withstand earthquakes according to Scinopharm, which told us such measures allowed its Tainan plant to survive a quake that felled a neighbouring tower block last week.
A newly established trade group has invited chemical manufacturers to apply for membership and announced plans to look at API and pharma-related issues.
The new report indicates that the US CMO market is poised for significant growth and urges international companies to enter the market – or be left behind.
Envirotainer has partnered with Air China Cargo in deal that will see local and international drug and API makers use its range of cold chain shipping containers.
Novasep has announced it is expanding API synthesis its facility in Boothwyn, Pennsylvania and confirmed that US growth is important after the sale of Pharmachem.
Incoming Indonesian government measures to attract foreign manufacturing joint ventures (JVs) could include a regulation to reduce API imports, Vincent Harijanto, committee head GP Farmasia said.
Ipca has received an FDA Warning Letter at three Indian API facilities, but says it awaits re-inspection after already rectifying issues highlighted in a 2014 Form 483.
